ВЛИЯНИЕ БЛОКАДЫ РЕНИН-АНГИОТЕНЗИН-АЛЬДОСТЕРОНОВОЙ СИСТЕМЫ НА ТЕЧЕНИЕ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ
- Авторы: Романова ЕЕ1, Кириченко АА2, Romanova EE3, Kirichenko AA3
-
Учреждения:
- Центральная поликлиника ОАО РЖД, Москва
- Кафедра терапии ГОУ ДПО РМАПО, Москва
- Выпуск: № 11 (2009)
- Страницы: 18-21
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/277293
- ID: 277293
Цитировать
Полный текст
Аннотация
Несмотря на большие успехи в понимании многих электрофизиологических механизмов формирования и поддержания фибрилляции предсердий (ФП), сегодня не существует универсального метода ее лечения. Применение антиаритмических лекарственных средств с целью удержания синусового ритма ограничивается их недостаточной эффективностью. Есть основания полагать, что блокада ренин-ангиотензин-альдостероновой системы может уменьшить число впервые выявленных эпизодов ФП, а также предотвратить рецидивы ФП. Рассмотрены результаты исследований влияния ингибиторов ангиотензинпревращающего фермента и блокаторов рецепторов ангиотензина II на развитие и течение ФП. Эти препараты оказались способными предотвращать ФП и ее осложнения, вероятно за счет обратного развития структурного и функционального ремоделирования миокарда.
Об авторах
Е Е Романова
Центральная поликлиника ОАО РЖД, МоскваЦентральная поликлиника ОАО РЖД, Москва
А А Кириченко
Кафедра терапии ГОУ ДПО РМАПО, МоскваКафедра терапии ГОУ ДПО РМАПО, Москва
E E Romanova
A A Kirichenko
Список литературы
- Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-19.
- Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
- Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84.
- Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005;36:1115-19.
- Verdecchia P, Reboldi R, Bentivoglio M, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 2003;41:218-23.
- Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-69.
- Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction the GISSI-3 data. Heart 2001;86:527-32.
- Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction Circulation 1999;100:376-80.
- Van den Berg MP, Crijns HJGM, van Veldhuisen DJ, et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation J Card Fail 1995;1:355-63.
- Vermes E, Tardif J-C, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction Circulation 2003;107:2926.
- Swedberg K, Pfeffer M, Coen-Solal A, et al. Prevention of atrial fibrillation in symptomatic chronic heart failure by candesartanresults from the CHARM study. J Am Coll Cardiol 2004;43(Suppl. A):222A.
- Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999;353:611-16.
- Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999;354:1751-56.
- De Simone A, De Pasquale M, De Matteis C, et al. Verapamil Plus Antiarrhythmic Drugs Reduce Atrial Fibrillation Recurrences After an Electrical Cardioversion (VEPARAF study). Eur Heart J 2003;24:1425-29.
- Schmieder RE, Schlaich MP, Klingbeil AU, et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998;13:564-69.
- Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003;24:2090-98.
- Madrid AH, Bueno MG, Rebollo JMG, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. Circulation 2002;106:331-36.
- Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-77.
- Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of atrial fibrillation substrate in dogs with ventricular tachycardia-induced congestive heart failure. Circulation 2001;104:2608-14.
- Goette A, Lendeckel U, Klein HU. Signal transduction systems and atrial fibrillation. Cardiovasc Res 2002;54:247-58.
- Tsang TS, Barnes ME, Bailey KR, et al. Left atrial volumeimportant risk marker of incident atrial fibrillation in 1655 older men and women. Mayo Clin Proc 2001;76:467-75.
- Vaziri SM, Larson MG, Benjamin EJ, et al. Echocardiographic predictors of nonrheumatic atrial fibrillation the Framingham Heart Study. Circulation 1994;89:724-30.
- Kalifa J, Jalife J, Zaitsev AV, et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. Circulation 2003;108:668-71.
- Morillo CA, Klein GJ, Jones DL, et al. Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 1995;91:1588-95.
- Ravelli F, Allessie M. Effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Langendorff-perfused rabbit heart. Circulation 1997;96:1686-95.
- Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-68.
- Shi Y, Ducharme A, Li D, Gaspo R, et al. Remodeling of atrial dimensions and emptying function in canine models of atrial fibrillation. Cardiovasc Res 2001;52:217-25.
- Li D, Fareh S, Leung TK, et al. Promotion of atrial fibrillation by heart failure in dogs atrial remodeling of a different sort. Circulation 1999;100:87-95.
- Shi Y, Tardif J-C, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002;54:456-61.
- Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-17.
- http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2333&mid=1085056570&magid=175&full=1